Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations

Future Oncol. 2005 Jun;1(3):319-22. doi: 10.1517/14796694.1.3.319.
No abstract available

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics*
  • Antineoplastic Agents / therapeutic use
  • ErbB Receptors / genetics*
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Mutation / genetics*

Substances

  • Antineoplastic Agents
  • ErbB Receptors